AbbVie in recent weeks sued Novartis’ Sandoz and four other generic drugmakers over copies of its immunology drug Rinvoq (upadacitinib). Though Rinvoq’s U.S. patents won’t begin to expire until 2033, the suit aims to stop any generic versions from being marketed ahead of those expirations. The JAK inhibitor was first approved in 2019 for the treatment of moderate to severe rheumatoid arthritis, an indication for which it currently holds covered or better status for 97% of all insured lives. 35% of covered lives have preferred access to Rinvoq, largely with utilization management restrictions applied. Norstella’s Evaluate Pharma projects the drug will generate $3.8 billion in global sales by the end of 2023.